We’re honored to share our exclusive interview with Lorna Warick, CEO of Lymphoma Coalition. In this session, we explore the ...

Technology Meets Compassion. At its core, the START Hope Hub is both a technical innovation and a human-centered service. It offers an intuitive interface where users—patients, caregivers, or ...

About ONCOLife. ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ...

The Phase III IMforte study shows that adding lurbinectedin to Tecentriq for ES-SCLC first-line maintenance reduced disease progression or death risk by 46% and death risk by 27%. Median PFS improved ...

A Broader Vision for Oncology Innovation “VVD-214 is showing promising potential to improve treatment options for patients suffering from MSI-high cancers, a population with high unmet medical need,” ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease progression or death by 44% compared to taxane, trastuzumab, and pertuzumab ...

Specifically, treatment with darolutamide plus ADT resulted in a 5.1-month extension in time to deterioration of the Functional Assessment of Cancer Therapy–Prostate (FACT-P) total score compared to ...

BioNTech and Bristol Myers Squibb have partnered to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A in over 10 solid tumor indications. The ...

A Canadian Cancer Society-funded trial shows a 3-year structured exercise program post-chemotherapy improves survival for colon cancer patients. Involving 889 participants, the trial saw a 28% ...

The Elinzanetant Clinical Development Program. The Phase III OASIS program for elinzanetant includes four international trials: OASIS-1 and -2 evaluated the drug’s safety and efficacy for menopausal ...

A Potential New Standard of Care “The landmark data for the inavolisib-based regimen showed not only a doubling in progression-free survival, but importantly that it extended lives and gave people ...

The new data from the PERSEUS and CEPHEUS studies show that DARZALEX FASPRO®-based regimens achieve up to 95% 4-year PFS and over 55% sustained MRD negativity in transplant-eligible patients, and 69% ...